ライフサイエンスコーパス: lowering

1 CI: 0.43 to 0.99) compared with standard BP lowering.

2 ce due to the negative drain-induced barrier lowering.

3 Bimatoprost SR provided rapid, sustained IOP lowering.

4 similar low-density lipoprotein cholesterol lowering.

5 ay be on the rise in an era of intense lipid lowering.

6 the forbidden IR active mode due to symmetry lowering.

7 ansitions take place accompanied by symmetry lowering.

8 se as dietary ingredients with serum glucose lowering activity in humans.

9 g IOP in patients who require additional IOP lowering after a first AGV.

10 igger cardiac dysfunction and that a glucose-lowering agent can correct it.

11 The role of the arginine-lowering agent pegylated arginine deiminase (ADI-PEG20)

12 rmore, treating zebrafish with a cholesterol-lowering agent, ezetimibe, reduced susceptibility to S T

13 T: Atorvastatin calcium (ATV), a cholesterol-lowering agent, suffers from poor systemic availability

14 after treatment with probucol, a cholesterol-lowering agent.

15 bidities, treatment (the use of oral glucose-lowering agents and insulin), control (hyperglycemia, dy

16 the lipid pathway, and the effects of lipid-lowering agents on reducing the incidence of OA.

17 NSAIDs] or aspirin, 17 hormones, and 7 lipid-lowering agents).

18 is one of the promising targets for glucose-lowering agents, and the development of GK activators ar

19 None of the four 25OHD-lowering alleles were associated with asthma, atopic der

20 ffective ammonia-lowering therapies, whether lowering ammonia restores proteostasis and increases mus

21 agonist may afford a new strategy for lipid-lowering and CVD risk reduction.

22 Lowering and individualizing the current amplitude in el

23 that should be tolerated during intensive BP lowering and its association with risk of ESRD are uncle

24 uncating) variant in APOC3 reported to be TG lowering and protective against CHD.

25 c-like, anxiolytic, weight-reducing, glucose-lowering, and wake-promoting activities.

26 fect the initiation of Abeta pathology while lowering apoE after Abeta seeding modulates plaque size

27 These results suggest that lowering apoE levels prior to plaque deposition can stro

28 s of intensive systolic blood pressure (SBP) lowering are unclear.

29 In the Lipid-Lowering Arm of the Anglo-Scandinavian Cardiac Outcomes

30 lines in kidney function in the intensive BP lowering arm of two trials in CKD associated with higher

31 lo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm] and JUPITER [Justification for the Use of

32 Mechanistically, lowering BAFF levels also diminished the number of T cel

33 nknown whether intensive blood pressure (BP) lowering beyond that recommended would lead to more lowe

34 Lowering blood glucose using a sodium-glucose cotranspor

35 Lowering blood pressure with celiac ganglionectomy in SH

36 ned, and no mechanistic studies of the Lp(a) lowering by alirocumab in humans have been published to

37 In vivo PCSK9 lowering by oral dosing of the candidate prodrug and qua

38 d hepatic LDL receptors as the basis for LDL lowering by PCSK9 inhibitors, there have been no human s

39 tailed interrogation of the mechanism of TRL lowering by the APOC3 Ala43Thr (A43T) variant, the only

40 ry, and mechanistic studies indicate glucose lowering by these procedures is driven by GLP-1.

41 ects that are independent of LDL-cholesterol lowering called pleiotropic effects.

42 rating that, in ambient air, surface tension lowering can prevail over the reduction in the Raoult ef

43 some probiotic bacteria possess cholesterol-lowering capabilities.

44 Surface tension lowering caused by organic surfactants, which diminishes

45 a3beta4)2beta4-nAChR function principally by lowering cell-surface expression, whereas single-channel

46 primarily the biomass of benthic consumers, lowering competition.

47 Lowering device voltage to avoid this issue is hindered

48 5% to <20% eGFR decline during intensive BP lowering did not associate with a higher risk of ESRD in

49 idence that the benefit of the intensive SBP lowering differed by baseline DBP.

50 Lowering DNMT1 below a threshold level is required for m

51 mHg (aHR, 4.86) and prior/current use of IOP-lowering drops or surgery in the other eye (aHR, 4.17);

52 rome-related conditions, such as any glucose-lowering drug (PR = 0.28; 95% CI = 0.25-0.31) and lipid-

53 -induced LCH-like mouse with the cholesterol-lowering drug atorvastatin ameliorated the pathology, im

54 ouseholds able to afford four blood pressure-lowering drug classes were more likely to use at least o

55 nti-inflammatory and low-density lipoprotein-lowering drugs are currently being investigated in large

56 tients who filled a prescription for glucose-lowering drugs between 2012 and 2015 were included and f

57 as matched with three users of other glucose-lowering drugs by use of propensity scores.

58 ingle capsule containing four blood pressure-lowering drugs each at quarter-dose (irbesartan 37.5 mg,

59 of SGLT2 inhibitors and use of other glucose-lowering drugs for non-fatal myocardial infarction, non-

60 nitiated on any SGLT-2i versus other glucose-lowering drugs in 6 countries to determine if these bene

61 treatment with SGLT-2i versus other glucose-lowering drugs was associated with a lower risk of HHF a

62 ity of two or more classes of blood pressure-lowering drugs was lower in low-income and middle-income

63 study drug classes for detailed drugs (lipid-lowering drugs, gastroesophageal reflux disease drugs, a

64 d nondetailed drugs in 8 drug classes (lipid-lowering drugs, gastroesophageal reflux disease drugs, d

65 Compared with other glucose-lowering drugs, use of SGLT2 inhibitors was associated w

66 Use of SGLT-2i, versus other glucose-lowering drugs, was associated with lower rates of HHF (

67 mortality compared with use of other glucose-lowering drugs-a finding consistent with the results of

68 T2 inhibitors and new users of other glucose-lowering drugs.

69 P-1) receptor agonists are effective glucose-lowering drugs.

70 2) What is the optimal target for BP lowering during antihypertensive therapy in adults?

71 ration progresses by up-regulating SUSD2 and lowering ECAD levels.

72 ch thickens Lo domains and disperses them by lowering edge energy on domain boundaries, left integrin

73 lower day-to-day variability in the glucose-lowering effect and lower rates of hypoglycemia among pa

74 Saponins have plasma cholesterol lowering effect in humans and are important in reducing

75 FBX had a modest systolic BP-lowering effect in T1D patients (112 +/- 10 to 109 +/- 9

76 te the safety and intraocular pressure (IOP)-lowering effect of a biodegradable bimatoprost sustained

77 BNP did not, highlighting the blood pressure-lowering effect of ANP in the general population.

78 In contrast, the chronic glucose-lowering effect of leptin in a STZ-induced mouse model o

79 The lipid-lowering effect of pravastatin was accompanied by select

80 e to determine that the intraocular pressure-lowering effect of pregabalin is dependent on the Cacna2

81 n nonathletes, and in all subjects, the rate-lowering effect of the HCN selective blocker, ivabradine

82 tection, independent from its blood pressure lowering effect, have not yet been fully understood.

83 Furthermore, AAT3 augments LDL cholesterol-lowering effects of ApoB-ASO.

84 report that Gleevec also achieves its Abeta-lowering effects through an additional cellular mechanis

85 The pooled placebo-corrected blood pressure-lowering effects were 5/2 mm Hg and 7/5 mm Hg, respectiv

86 olydextrose (PDX), a soluble fiber has lipid lowering effects.

87 lfonylurea drugs to exert their full glucose-lowering effects.

88 al proof of principle for the blood-pressure-lowering efficacy of renal denervation.

89 rize the 12-month intraocular pressure (IOP)-lowering efficacy of selective laser trabeculoplasty (SL

90 ary, this study demonstrates the cholesterol-lowering efficacy of short-term feeding of the Lab4 prob

91 mice and we reversed MA preference/taking by lowering endogenous glutamate and/or Homer2 expression w

92 We report that lowering expression of STIM1, the gene that encodes STIM

93 By significantly lowering financial thresholds, this powerful cardiac ele

94 pertensive medication, and more intensive BP lowering for many adults taking antihypertensive medicat

95 pertensive medication, and more intensive BP lowering for many adults taking antihypertensive medicat

96 These findings support more effective LDL-C lowering for primordial prevention, even in individuals

97 Zn(2+), increasing cytosolic free Zn(2+) and lowering free Zn(2+) in the S(E)R.

98 tional decision making and may contribute to lowering healthcare costs.

99 ute eGFR declines >/=20% during intensive BP lowering identified a subset of patients at higher risk

100 Lowering immunosuppression is the only established appro

101 gent now exists to target further heart rate lowering in patients who have been stable on a "maximall

102 trials (RCTs) to assess whether intensive BP lowering in patients with acute ICH is safe and effectiv

103 rials of early intensive blood pressure (BP) lowering in patients with ICH (<6 hours) and elevated sy

104 ction, resulting in less potency for glucose lowering in patients with kidney disease.

105 s will determine cardiorenal outcomes of PUA lowering in patients with T1D.

106 Syn but not monomeric alphaSyn was causing a lowering in synapsin-I/II protein abundance.

107 cular disease (CVD) benefits of intensive BP lowering in this population.

108 Intensive SBP lowering increased risk for incident CKD events, but thi

109 protective, hepatoprotective and cholesterol lowering ingredients.

110 e system are then offered, with the goals of lowering insurance premiums, improving coverage rates, a

111 ria for causality, we conclude strongly that lowering intake of saturated fat and replacing it with u

112 Lipoprotein(a)-lowering interventions could be preferentially effective

113 analostomy/Phacoviscocanalostomy (VC/PVC) in lowering intraocular pressure (IOP) in Normal Tension Gl

114 with intensive systolic blood pressure (SBP) lowering is unclear.

115 is population and its CD40 expression, while lowering its CD134 expression, thereby confirming its ro

116 on in contrast volumes across physicians and lowering its use in higher-risk patients.

117 of dense lattice dislocations as a means of lowering kappaL , but also the importance of engineering

118 nce for the short- and long-term benefits of lowering LDL-C for the primary prevention of cardiovascu

119 CVD, and clinical trial data have shown that lowering LDL-C generally reduces cardiovascular risk.

120 nts, suggesting that the clinical benefit of lowering LDL-C may depend on how LDL-C is lowered.

121 ors (statins) have been the main therapy for lowering LDL-C.

122 ved assessment of the efficacy and safety of lowering low-density lipoprotein cholesterol levels with

123 outs were not completely reversed by ammonia-lowering measures.

124 Purpose Cholesterol-lowering medication (CLM) has been reported to have a ro

125 Conclusion Cholesterol-lowering medication during adjuvant endocrine therapy ma

126 secondarily, leads to a reduction in glucose-lowering medication in participants with type 2 diabetes

127 early and prolonged use of antiviral and IOP-lowering medication may prevent glaucoma.

128 Rescue topical IOP-lowering medication or a single repeat treatment with im

129 cket cost (copay), clinical diagnoses, lipid-lowering medication use, and low-density lipoprotein cho

130 patients who reported currently taking lipid-lowering medication, full implementation of the USPSTF r

131 an-diagnosed diabetes, or the use of glucose-lowering medication.

132 the secondary outcome reductions in glucose-lowering medication.

133 d be treated sufficiently with primarily IOP lowering medications and without need for glaucoma surge

134 OAG were randomized to prompt washout of IOP-lowering medications followed by SLT, 3-month delay foll

135 ts that, for patients requiring multiple IOP-lowering medications, a fixed combination may provide im

136 nded by postrandomization use of cholesterol-lowering medications.CVD risk in postmenopausal women ap

137 re likely to use at least one blood pressure-lowering medicine (adjusted odds ratio [OR] 2.23, 95% CI

138 re likely to use at least one blood pressure-lowering medicine (adjusted OR 1.42, 95% CI 1.25-1.62; p

139 have access to more than one blood pressure-lowering medicine and, when available, they are often no

140 Ensuring access to affordable blood pressure-lowering medicines is essential for control of hypertens

141 useholds unable to afford two blood pressure-lowering medicines was 31% in low-income countries (1069

142 re those in communities where blood pressure-lowering medicines were not available.

143 , costs, and affordability of blood pressure-lowering medicines with data recorded from 626 communiti

144 lability and affordability of blood pressure-lowering medicines, and the association with use of thes

145 ce, its charge, by approximately 0.27 units, lowering mobility.

146 cardiovascular risk reduction through LDL-C lowering need to be applied in patients experiencing int

147 optosis in tissues and cell culture and that lowering O-GlcNAcylation induces cell death.

148 Rhizobiales bacteria possibly contributed to lowering O2 levels in leaf pockets but did not release d

149 nia-lowering therapy resulted in significant lowering of blood and skeletal muscle ammonia, increase

150 NTRODUCTION: It is unclear whether intensive lowering of blood pressure (BP) at the acute phase of in

151 muscle (VSM) allows for vasodilation without lowering of cytosolic Ca(2+).

152 Our results illustrate that the lowering of disease burden in highly modular social netw

153 INTERPRETATION: The absence of a lowering of HIV incidence in universal test and treat cl

154 ally elevate ICP but does prevent the normal lowering of ICP when upright.

155 iate management including ocular massage and lowering of intraocular pressure, the visual loss remain

156 clerotic cardiovascular disease benefit from lowering of LDL cholesterol levels below current targets

157 he patients and significantly attenuated the lowering of LDL cholesterol levels.

158 system's line tension energy, because of the lowering of line interface energy closer to mixing.

159 lisin-kexin type 9 (PCSK9), a target for the lowering of low-density lipoprotein (LDL) cholesterol.

160 anacetrapib seems to be largely explained by lowering of non-HDL-C (high-density lipoprotein choleste

161 y in a nontrial setting leads to significant lowering of PA pressures.

162 Their primary mechanism of action is the lowering of serum cholesterol through inhibiting hepatic

163 Raoult effect, while maintaining substantial lowering of surface tension, even for partial surface co

164 ivity resulted from a chiral anion dependent lowering of the activation barrier for the desired pathw

165 R , leading to luminal RyR sensitization and lowering of the activation threshold for cytosolic CICR.

166 zation of the transition state and a further lowering of the Cope barrier.

167 ly, leading to luminal RyR sensitization and lowering of the cytosolic Ca(2+) activation threshold.

168 litates these cyclocondensation reactions by lowering of the energy barrier.

169 rease in acceptor strength, which results in lowering of the HOMO-LUMO gap.

170 yers, suggesting that BAM catalysis involves lowering of the kinetic barrier imposed by the hydrophob

171 in strong intramolecular charge transfer and lowering of the LUMO energy level.

172 The precise lowering of the ME/WE plane toward the IRE was enabled b

173 g beyond that recommended would lead to more lowering of the risk of left ventricular hypertrophy (LV

174 at room temperature and therefore precludes lowering of the supply voltage and overall power consump

175 he above effect and a proportionally greater lowering of the vesicle lysis tension and hydration repu

176 to hexapeptide association, as manifested by lowering of transient interactions between the central a

177 We aimed to assess the benefits of LDL-C lowering on cardiovascular outcomes among individuals wi

178 hazard ratio of intensive versus standard BP lowering on CVD, 0.76 [95% confidence interval, 0.64-0.9

179 To examine the effects of intensive SBP lowering on kidney and cardiovascular outcomes and contr

180 Our aim was to determine the impact of PUA lowering on renal and vascular function in patients with

181 The effect of intensive BP lowering on significant haematoma expansion at 24 hours

182 The effect of lipid lowering on the incidence of deep venous thrombosis (DVT

183 acute ICH randomised to either intensive BP-lowering or standard BP-lowering treatment protocols.

184 ms of reducing unscheduled physician visits, lowering patients' anxiety and increasing self-efficacy,

185 estigate the associations of LDL cholesterol-lowering PCSK9 variants with type 2 diabetes and related

186 To evaluate the intraocular pressure (IOP)-lowering performance and safety of an ab interno gelatin

187 SERS sensor involved drug release induced by lowering pH and increasing GSH levels, both occurring in

188 reasing curcumin-SSPS mixture to pH 12.0 and lowering pH to 7.0.

189 risk of death, which is possibly mediated by lowering plasma phosphate.

190 oting template-polymer interactions, thereby lowering polymer nucleation barrier.

191 Finally, we show that whether lowering population growth entails overall improvements

192 plements has an equally beneficial effect on lowering postprandial glucose.The aim of our study was t

193 has also been suggested that the cholesterol-lowering potential of KJM may be greater than that of ot

194 rmine whether aggressive blood pressure (BP) lowering prevents recurrent atrial fibrillation (AF) aft

195 Glucose lowering remains important for the prevention of long-te

196 e demonstrated a direct relationship between lowering remotely monitored PA pressures and heart failu

197 It can be assumed that by lowering rennet pH, milk pH decreases, causing a signifi

198 Lowering SERCA level will enable intracellular calcium o

199 Current guidelines recommend lowering serum phosphate concentrations toward normal.

200 We evaluated whether lowering serum uric acid levels with allopurinol improve

201 teractions and hydrogen bonds, respectively, lowering significantly the binding constants.

202 The group with intensive LDL-c-lowering statin had an 18% increase in the likelihood of

203 ssed the efficacy and safety of intensive BP-lowering strategies in older (age >/=65 years) hypertens

204 Huntingtin-lowering strategies include antisense oligonucleotides a

205 without glaucoma progression/additional IOP-lowering surgery), Snellen-equivalent visual acuity (VA)

206 n oligomers can impair memory by selectively lowering synapsin expression.

207 The effects of lowering systemic VEGF levels on the developing organ sy

208 ial): 4086 randomly assigned to intensive BP lowering (target SBP <120 mm Hg) and 4078 assigned to st

209 <120 mm Hg) and 4078 assigned to standard BP lowering (target SBP <140 mm Hg).

210 nsion but no diabetes mellitus, intensive BP lowering (target systolic BP <120 mm Hg) compared with s

211 lic BP <120 mm Hg) compared with standard BP lowering (target systolic BP <140 mm Hg) resulted in low

212 l cultures lithium attenuates iron efflux by lowering tau protein that traffics amyloid precursor pro

213 By lowering temperature, DNA hybridization is also promoted

214 Therefore, lowering the accumulation of autophagosomes may represen

215 smitted to its nucleotide binding site, thus lowering the affinity for ATP.

216 nd myriad risks and benefits associated with lowering the age of enrollment on oncology clinical tria

217 Greatly lowering the aggregation propensity of any one single si

218 responses of Hc protein structure to HHP for lowering the allergenicity of squid.

219 tron density into the metal nanocluster thus lowering the barrier for bromobenzene activation.

220 reduction in adipocyte lipolysis in mice by lowering the bioavailability of noradrenaline.

221 Lowering the bulk pH in the media allowed us to isolate

222 Here, by lowering the carrier density in Cd3As2 nanoplates, we ob

223 necessary for survival, thereby collectively lowering the chances of starving.

224 citations can be dynamically switched off by lowering the chemical potential of graphene.

225 the Econamine process, without significantly lowering the CO2 absorption efficiency ( approximately 9

226 has been identified as a restriction factor, lowering the concentration of dNTP substrates to limit R

227 8 trial), treatment intensity was reduced by lowering the cumulative dose of etoposide (950 to 450 mg

228 Lowering the cut point to capture all type 1 ROP cases (

229 Lowering the DNA replication initiation rate by introduc

230 te, clinicians often manage this disorder by lowering the dose of, or discontinuing, the causative dr

231 an exclusively thermodynamic manner, i.e. by lowering the free energy of the native state and with al

232 e presence of the amphiphilic replicator, by lowering the interfacial tension between droplets of the

233 involved preconcentration of analytes, thus lowering the limit of detection (LOD) to the nanograms p

234 oncentrated on the coating, and dramatically lowering the limits of detection attained by sole DART a

235 ling of the backbone while also dramatically lowering the LUMO energy.

236 onal cohort in years with early ice breakup, lowering the mean size of age 0 fish.

237 gs showed enhanced antibacterial activities, lowering the minimum inhibitory concentration (MIC) by m

238 the interaction with the H(+) is involved in lowering the O-O cleavage barrier.

239 Current approaches to lowering the pH of basic media rely on the addition of a

240 to boost the rate of enzyme inactivation by lowering the pKa of their alpha-protons.

241 1 (Gpa2CN/Rx1L) results in autoactivity, but lowering the protein levels restored its specific activa

242 The focus should instead shift toward lowering the rate of reinterventions and pacemaker impla

243 Therefore, strategies aiming at lowering the risk of AF development and progression are

244 The use of toppings masked the effect of lowering the sodium content, allowing to increase the re

245 Here, by lowering the temperature to 80 K, we have been able to s

246 iation and germinal center (GC) formation by lowering the threshold of antigen-driven activation.

247 the MTD are as efficacious, suggesting that lowering the total amount of drug administered could low

248 content of these constituents in the foods, lowering their bioactive properties.

249 se findings suggest surgeons should consider lowering their threshold for using arterial grafts, and

250 or preclinical screening of personalized HTT lowering therapies in HD patients of East Asian descent.

251 espite the availability of effective ammonia-lowering therapies, whether lowering ammonia restores pr

252 derate-strength evidence suggests that urate-lowering therapy (allopurinol or febuxostat) reduces lon

253 foundly altered in HCV-positive men by lipid lowering therapy (change in HR with lipid-lowering thera

254 to high-intensity statin and nonstatin lipid-lowering therapy (LLT) were analyzed before (September 1

255 fed Sprague-Dawley rats treated with ammonia-lowering therapy by l-ornithine l-aspartate and rifaximi

256 Urate-lowering therapy decreases serum urate levels and reduce

257 erolaemia who were on stable LDL cholesterol-lowering therapy for at least 4 weeks; all patients rece

258 id lowering therapy (change in HR with lipid-lowering therapy for TC >240 mg/dL from 1.82 to 1.19 [HC

259 ning potential benefits of combination lipid-lowering therapy in individuals with CKD are needed.

260 Consistently, 4 weeks of ammonia-lowering therapy resulted in significant lowering of blo

261 Ammonia-lowering therapy results in improvement in skeletal musc

262 Lipid lowering therapy significantly reduces this risk, with m

263 and lay the foundation for prolonged ammonia-lowering therapy to reverse sarcopenia of cirrhosis.

264 L-c is reduced by more than 30% during lipid-lowering therapy, blood glucose monitoring is suggested

265 rences with patients before initiating urate-lowering therapy, including concomitant prophylaxis, in

266 uding enzyme replacement therapy, oral lipid-lowering therapy, stem-cell transplantation, and liver t

267 ry low levels when added to background lipid-lowering therapy.

268 Allopurinol (AP) is administered in UA lowering therapy.

269 rats were reversed by treatment with ammonia-lowering therapy.

270 .03; 95% CI: 1.30 to 3.18) with intensive BP-lowering therapy.

271 -cholesterol concentration, and use of lipid-lowering therapy.

272 In conjunction with slight barrier lowering, these two effects are sufficient to explain th

273 2) systolic BP lowering to a target of <130 mm Hg may reduce the risk o

274 t per protein molecule could be minimized by lowering transcription levels, regulating translation sp

275 ensive BP-lowering treatment and standard BP-lowering treatment (OR: 0.99; 95% CI: 0.82 to 1.20, p=0.

276 ia) and also evaluated the effect of ammonia-lowering treatment (ornithine phenylacetate [OP]).

277 between patients randomised to intensive BP-lowering treatment and standard BP-lowering treatment (O

278 isk associated with intensive blood pressure-lowering treatment can be established only via randomize

279 Patients discontinued all lipid-lowering treatment except ezetimibe and/or apheresis.

280 ifferences between intensive and standard BP lowering treatment groups in total mortality rates, unfa

281 surgery in many patients, and increased IOP-lowering treatment in the postoperative course was commo

282 t-effectiveness significantly increases when lowering treatment prices in early fibrosis stages.

283 either intensive BP-lowering or standard BP-lowering treatment protocols.

284 o compare intraocular pressure (IOP) and IOP-lowering treatment requirements in patients with late in

285 Intensive BP-lowering treatment showed a (non-significant) trend for

286 It is unknown whether adding triglyceride-lowering treatment to statin reduces this risk.

287 operation group, respectively, required IOP-lowering treatment with glaucoma medications added, adju

288 After 6 months of cholesterol-lowering treatment, only MR imaging measurements of tend

289 ), of whom several required preoperative IOP-lowering treatment.

290 conducted six parallel, multinational lipid-lowering trials enrolling 4300 patients with hyperlipide

291 ilitate the development of new therapies for lowering TRL levels.

292 Barrier lowering upon slight increase in layer spacing ( approxi

293 fluenza viruses by lessening weight loss and lowering viral loads.

294 The limits of lowering Vt have not yet been established, and some pati

295 Intensive BP lowering was associated with a 29% reduction in MACE (RR

296 resumably occur independent of blood glucose lowering, we also explore the potential use of SGLT2 inh

297 signed to the intensive (versus standard) BP lowering were 66% more likely to regress/improve their L

298 lycemic conditions at baseline and after PUA lowering with febuxostat (FBX) for 8 weeks.

299 uman activities have resulted in water table lowering (WTL) and enhanced nitrogen (N) deposition in T

300 nd Vascular Inflammation by Aggressive Lipid Lowering [YELLOW II]; NCT01837823).